









Markets
/
Stocks
/
nasdaq-rprx
/

Royalty Pharma PLC

RPRX

37.840USD

+0.540+1.45%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

16.36BMarket Cap

16.03P/E TTM



Royalty Pharma PLC

37.840

+0.540+1.45%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Royalty Pharma PLC

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Royalty Pharma PLC's Score

Industry at a Glance

Industry Ranking

10 / 159

Overall Ranking

32 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

43.485

Target Price

+16.58%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Royalty Pharma PLC Highlights

StrengthsRisks

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.26B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 43.83%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 43.83%.

Fairly Valued

The company’s latest PE is 16.42, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 334.97M shares, decreasing 7.13% quarter-over-quarter.

Held by Andreas Halvorsen

Star Investor Andreas Halvorsen holds 2.60M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 8.91, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 578.66M, representing a year-over-year increase of 7.71%, while its net profit experienced a year-over-year increase of 70.42%.

Score

Industry at a Glance

Previous score

8.91

Change



Financials

6.76

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.66

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

9.14

Key Metrics

Free cash flow

No Data

Royalty Pharma PLC's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 7.60, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 16.42, which is 2353.43% below the recent high of 402.86 and 42.13% above the recent low of 9.50.

Score

Industry at a Glance

Previous score

7.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 10/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.22, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Royalty Pharma PLC is 42.50, with a high of 54.00 and a low of 34.67.

Score

Industry at a Glance

Previous score

8.22

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

43.485

Target Price

+16.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Royalty Pharma PLC

RPRX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 9.22, which is higher than the Pharmaceuticals industry's average of 6.89. Sideways: Currently, the stock price is trading between the resistance level at 38.87 and the support level at 36.02, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.69

Change

0.53

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.171

Buy

RSI(14)

61.431

Neutral

STOCH(KDJ)(9,3,3)

81.634

Buy

ATR(14)

0.818

High Vlolatility

CCI(14)

126.755

Buy

Williams %R

11.061

Overbought

TRIX(12,20)

0.144

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

37.258

Buy

MA10

37.091

Buy

MA20

36.708

Buy

MA50

36.255

Buy

MA100

36.211

Buy

MA200

34.383

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 5.74. The latest institutional shareholding proportion is 77.49%, representing a quarter-over-quarter decrease of 16.46%. The largest institutional shareholder is Baillie Gifford, holding a total of 17.37M shares, representing 4.02% of shares outstanding, with 26.32% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Morgan Stanley Investment Management Inc. (US)

35.86M

+8.31%

Fidelity Management & Research Company LLC

35.31M

+2.58%

Nogra Group Sicaf SIF S.A.

29.93M

-16.88%

Capital International Investors

21.88M

Baillie Gifford & Co.

Star Investors

18.02M

+34.46%

BlackRock Institutional Trust Company, N.A.

16.87M

+3.94%

Swedbank Robur Fonder AB

12.16M

The Vanguard Group, Inc.

Star Investors

36.17M

-0.84%

State Street Investment Management (US)

10.19M

+7.13%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 9.18, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.47. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.